• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

A Top Biotechnology Play for 2021

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.
By JAMES "REV SHARK" DEPORRE
Jan 19, 2021 | 02:07 PM EST
Stocks quotes in this article: FBRX

This very thin stock is well under the radar, but it has the potential to offer some of the most important data for mid-stage biotechnology stocks later this year. 

Biotechnology stocks can be very challenging to trade. Most of the time the key factor that determines their movement is expectations for the next data they may issue on key drugs under development. The stock can trade quite erratically when the data isn't due for months, especially if it trades little volume.

One stock that is trading that way right now is Forte Biosciences (FBRX) . It is driving around in a $10 point range and has an average daily volume of just around 65,000 shares. This stock is going to continue to trade erratically until it releases data sometime around mid-year.

An analyst at Chardan, Gbola Amusa, has set a price target of $115 on the stock and reiterated his buy rating after third-quarter earnings. He writes that "a positive Phase II result for FB-401 in 2021, if consistent with FB-401's prior phase I/IIa published data, would prove to the one of the most important readouts for a mid-stage biotech company in 2021 and would catalyze performance of the entire microbiome medicines space, with 'considerably more upside' for Forte."

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema. Eczema is an incurable inflammatory skin condition characterized by itchy, dry, scaly, rashy skin. There are around 20 million patients that suffer from it in the U.S., roughly half of them are children.

FB-401 is a water-based spray containing three-different strains of bacteria that have been shown to help repair tissue and reduce inflammation. The use of the microbiome in this manner is viewed as a key theme in biotechnology in the years ahead.

I believe it is likely that the FBRX story will gain traction within the next few months as investors look ahead to a mid-year readout. The company had positive data on September 9th that caused the stock to nearly double in a few weeks. I'm looking for a similar move on the next report. The company has FDA Fast Track Designation.

There is no rush to buy these shares as it will be a long wait until data hits. I've been a periodic buyer on weakness and a seller into strength and will continue that approach until we are closer to the data readout

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, James "Rev Shark" DePorre was Long FBRX.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology

More from Investing

Corrective Action Produces Fading Confidence and Technical Damage

James "Rev Shark" DePorre
Feb 26, 2021 5:08 PM EST

It's dangerous to have too much exposure now, but the potential for a good recovery is there once interest rate issues are digested.

I'm Intrigued by the Recent Pullback in Aurora Mobile

Timothy Collins
Feb 26, 2021 3:30 PM EST

While the Chinese company is still not profitable, it is cash flow positive.

Salesforce Gets a Quant Downgrade on Top of Weakening Charts

Bruce Kamich
Feb 26, 2021 12:50 PM EST

Here's what investors and traders need to think about.

My Preference Right Now Is to Buy Pre-Deals

Timothy Collins
Feb 26, 2021 12:36 PM EST

I've added a few names that I see as a great risk-reward because of the limited downside.

I've Been a Buyer Friday, Making Partial Buys Like I Always Do

James "Rev Shark" DePorre
Feb 26, 2021 12:07 PM EST

It's premature to predict that a low has been made, but plenty of stocks are quite washed-out already and are starting to find support.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login